Moreover, miR-182-5p mimic therapy leads to the inhibition of Th17 cell development through targeting TATA-Box Binding Protein Associated Factor 15 (TAF15), mitigating the severity of EAU in vivo. Hence, the miR-182-5p/TAF15 axis could be a promising therapeutic target for uveitis (Zhang et al., 2020). This evidence concerns the gene TAF15 and uveitis.